Amouyal Philippe 4

What Happened
Philippe Amouyal, a director of Lexicon Pharmaceuticals (LXRX), reported the exercise/conversion of derivative securities on June 3, 2026. The filing shows 89,312 shares acquired at $0.00 and a corresponding disposition of a derivative interest for 89,312 shares at $0.00 — consistent with restricted stock units (RSUs) vesting and converting into common stock. No cash was paid in connection with the conversion, and there is no sale of the resulting shares reported in this filing.

Key Details

• Transaction date: 2026-06-03; filing date: 2026-06-04 (timely).
• Reported entries: 89,312 shares acquired @ $0.00 (code M: exercise/conversion of derivative); 89,312 shares disposed as a derivative @ $0.00.
• Shares owned following the transaction: Not specified in this filing.
• Footnotes: F1 — RSUs vest 100% on the first anniversary of the grant; F2 — each RSU equals one contingent right to one share.
• No indication of a sale or 10b5-1 plan in this filing.

Context

• Code M covers conversion/exercise of derivative securities; here it reflects RSUs converting into common stock rather than an open‑market purchase or sale.
• Conversions of vested RSUs are routine compensation events for insiders and do not by themselves indicate a buy or sell decision.